Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.

Journal Article (Journal Article)

The development of an effective AIDS vaccine remains a challenge. Nucleoside-modified mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of immunization against infectious diseases in preclinical studies, and are being tested for SARS-CoV-2 in humans. A critical question is how mRNA-LNP vaccine immunogenicity compares to that of traditional adjuvanted protein vaccines in primates. Here, we show that mRNA-LNP immunization compared to protein immunization elicits either the same or superior magnitude and breadth of HIV-1 Env-specific polyfunctional antibodies. Immunization with mRNA-LNP encoding Zika premembrane and envelope or HIV-1 Env gp160 induces durable neutralizing antibodies for at least 41 weeks. Doses of mRNA-LNP as low as 5 μg are immunogenic in macaques. Thus, mRNA-LNP can be used to rapidly generate single or multi-component vaccines, such as sequential vaccines needed to protect against HIV-1 infection. Such vaccines would be as or more immunogenic than adjuvanted recombinant protein vaccines in primates.

Full Text

Duke Authors

Cited Authors

  • Saunders, KO; Pardi, N; Parks, R; Santra, S; Mu, Z; Sutherland, L; Scearce, R; Barr, M; Eaton, A; Hernandez, G; Goodman, D; Hogan, MJ; Tombacz, I; Gordon, DN; Rountree, RW; Wang, Y; Lewis, MG; Pierson, TC; Barbosa, C; Tam, Y; Matyas, GR; Rao, M; Beck, Z; Shen, X; Ferrari, G; Tomaras, GD; Montefiori, DC; Weissman, D; Haynes, BF

Published Date

  • April 9, 2021

Published In

Volume / Issue

  • 6 / 1

Start / End Page

  • 50 -

PubMed ID

  • 33837212

Pubmed Central ID

  • PMC8035178

Electronic International Standard Serial Number (EISSN)

  • 2059-0105

Digital Object Identifier (DOI)

  • 10.1038/s41541-021-00307-6


  • eng

Conference Location

  • England